Lazard Asset Management LLC Boosts Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Lazard Asset Management LLC lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 37.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,996 shares of the company's stock after purchasing an additional 12,583 shares during the quarter. Lazard Asset Management LLC owned 0.14% of TransMedics Group worth $2,867,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of TransMedics Group by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after purchasing an additional 40,860 shares during the period. FIL Ltd grew its stake in shares of TransMedics Group by 28.0% during the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after purchasing an additional 218,961 shares during the period. Braidwell LP acquired a new stake in shares of TransMedics Group during the 4th quarter worth approximately $57,493,000. Geode Capital Management LLC grew its stake in shares of TransMedics Group by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 772,744 shares of the company's stock worth $48,191,000 after purchasing an additional 8,954 shares during the period. Finally, Wasatch Advisors LP grew its stake in shares of TransMedics Group by 83.3% during the 4th quarter. Wasatch Advisors LP now owns 441,354 shares of the company's stock worth $27,518,000 after purchasing an additional 200,603 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the transaction, the director now owns 732 shares in the company, valued at $84,641.16. The trade was a 89.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Price Performance

TMDX traded down $0.10 on Thursday, hitting $121.21. 260,929 shares of the company's stock were exchanged, compared to its average volume of 1,352,789. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a 50-day moving average price of $87.35 and a 200-day moving average price of $76.74. The stock has a market cap of $4.10 billion, a price-to-earnings ratio of 129.17 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. During the same quarter in the previous year, the company posted $0.35 EPS. The firm's quarterly revenue was up 48.2% on a year-over-year basis. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on TMDX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Piper Sandler reissued an "overweight" rating and issued a $125.00 price target (up previously from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Finally, Oppenheimer lifted their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and an average price target of $126.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.